Director, Real-World Evidence & Health Outcomes, mRNA Vaccines

GSK•Durham, NC

5d•$203,775 - $339,625

About The Position

The Director, Real-World Evidence & Health Outcomes (RWE-HO), mRNA Vaccines provides scientific and strategic leadership for developing and delivering real-world evidence to support GSK’s mRNA vaccine portfolio, primarily focused on influenza. The role shapes evidence generation across late-stage development, launch, and post-marketing, with particular responsibility for post-marketing vaccine effectiveness studies in the United States. Working in a global, cross-functional environment, the Director translates recommendation and access evidence needs into scientifically rigorous and operationally feasible research. The role calls for expertise in US vaccine effectiveness research, influenza epidemiology, real-world data, and causal methods, as well as the ability to influence asset strategy and lead complex external collaborations. The successful candidate will design credible studies, anticipate methodological challenges, turn evidence needs into practical research, influence decisions, build external credibility, and deliver evidence supporting the value and appropriate use of GSK’s mRNA vaccines.

Requirements

PhD, ScD, DrPH, MD, PharmD, MPH, or equivalent advanced degree in epidemiology, public health, pharmacoepidemiology, health outcomes research, or a related quantitative discipline.
At least 5 years of experience in real-world evidence, epidemiology, or health outcomes research within the pharmaceutical or vaccine industry, academia, public health, or a comparable environment.
Experience designing, conducting, and interpreting post-marketing vaccine studies in the United States.
Research experience with vaccine effectiveness studies.
Experience using large US healthcare databases, including administrative claims, electronic health records, or linked real-world datasets.
Experience leading complex studies from concept through delivery, interpretation, and scientific dissemination.
Demonstrated effectiveness in global, cross-functional matrix teams and managing internal and external stakeholders.

Nice To Haves

Direct experience with influenza vaccine effectiveness studies in the United States.
Experience with US Medicare, commercial claims, EHR, and linked claims/EHR data.
Knowledge of US influenza vaccination recommendations, vaccine delivery, and healthcare systems.
Experience studying severe influenza, hospitalization, cardiovascular complications, or other downstream outcomes.
Experience leading global evidence-generation plans or multi-country observational studies.

Responsibilities

Lead and contribute to the integrated RWE-HO strategy for mRNA influenza vaccines, aligned with clinical development, medical, regulatory, and commercialization priorities.
Translate strategic evidence gaps into clear research questions and fit-for-purpose study designs across pre-launch, launch, and post-marketing phases.
Provide expert scientific input to governance decisions, investment choices, evidence prioritization, and risk mitigation.
Lead the design, implementation, and interpretation of post-marketing influenza vaccine effectiveness studies in the United States and other geographies.
Ensure studies meet appropriate standards of scientific rigor, transparency, reproducibility, and fitness for their intended decision-making purpose.
Build productive collaborations with US academic investigators, healthcare systems, data partners, and vaccine effectiveness research networks.
Partner with Clinical Development, Epidemiology, Medical Affairs, Regulatory, Safety, Biostatistics, Market Access, Data Science, and Commercial teams.
Lead multiple complex projects, budgets, and external research collaborations, ensuring quality, timely delivery, and appropriate escalation of risks.
Influence senior stakeholders without direct authority and communicate complex epidemiological concepts clearly and with a decision-focused approach.
Mentor colleagues and contribute to strengthening RWE-HO capabilities, standards, and innovation across the organization.